Cargando…

Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model

The use of a 10 gene transcriptional signature as part of the GARD model has been shown to be predictive of radiotherapy benefit for a range of cancers, with the potential to determine an optimal overall dose per patient. We used publicly available RNA-seq transcriptomics data from a luminal B breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Ben, O’Sullivan, Brian, Golden, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396042/
https://www.ncbi.nlm.nih.gov/pubmed/36017133
http://dx.doi.org/10.1016/j.ctro.2022.08.002
_version_ 1784771840646840320
author Nolan, Ben
O’Sullivan, Brian
Golden, Aaron
author_facet Nolan, Ben
O’Sullivan, Brian
Golden, Aaron
author_sort Nolan, Ben
collection PubMed
description The use of a 10 gene transcriptional signature as part of the GARD model has been shown to be predictive of radiotherapy benefit for a range of cancers, with the potential to determine an optimal overall dose per patient. We used publicly available RNA-seq transcriptomics data from a luminal B breast cancer patient and from 14 prostate cancer patients to explore the radiosensitivity indices (RSI) and so GARD estimates of both tumour and proximal normal biopsies from each individual. Clear differences of clinical relevance in derived radiobiological properties between tumour and proximal normal tissues were evident for the breast cancer patient, whilst such differences across the prostate cancer cohort were more equivocal. Using the prostate cancer cohort’s median tumour predicted GARD value as a threshold for high therapeutic effect for radiotherapy, we found evidence that a higher overall prescribed dose than the widely used 72 Gy/36fx could benefit half of these patients. This exploratory study demonstrates the potential combining the GARD model with sequencing based transcriptomics could have in informing personalised radiotherapeutic practise for both breast and prostate cancer patients.
format Online
Article
Text
id pubmed-9396042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93960422022-08-24 Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model Nolan, Ben O’Sullivan, Brian Golden, Aaron Clin Transl Radiat Oncol Technical Note The use of a 10 gene transcriptional signature as part of the GARD model has been shown to be predictive of radiotherapy benefit for a range of cancers, with the potential to determine an optimal overall dose per patient. We used publicly available RNA-seq transcriptomics data from a luminal B breast cancer patient and from 14 prostate cancer patients to explore the radiosensitivity indices (RSI) and so GARD estimates of both tumour and proximal normal biopsies from each individual. Clear differences of clinical relevance in derived radiobiological properties between tumour and proximal normal tissues were evident for the breast cancer patient, whilst such differences across the prostate cancer cohort were more equivocal. Using the prostate cancer cohort’s median tumour predicted GARD value as a threshold for high therapeutic effect for radiotherapy, we found evidence that a higher overall prescribed dose than the widely used 72 Gy/36fx could benefit half of these patients. This exploratory study demonstrates the potential combining the GARD model with sequencing based transcriptomics could have in informing personalised radiotherapeutic practise for both breast and prostate cancer patients. Elsevier 2022-08-09 /pmc/articles/PMC9396042/ /pubmed/36017133 http://dx.doi.org/10.1016/j.ctro.2022.08.002 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Technical Note
Nolan, Ben
O’Sullivan, Brian
Golden, Aaron
Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model
title Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model
title_full Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model
title_fullStr Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model
title_full_unstemmed Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model
title_short Exploring breast and prostate cancer RNA-seq derived radiosensitivity with the Genomic Adjusted Radiation Dose (GARD) model
title_sort exploring breast and prostate cancer rna-seq derived radiosensitivity with the genomic adjusted radiation dose (gard) model
topic Technical Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396042/
https://www.ncbi.nlm.nih.gov/pubmed/36017133
http://dx.doi.org/10.1016/j.ctro.2022.08.002
work_keys_str_mv AT nolanben exploringbreastandprostatecancerrnaseqderivedradiosensitivitywiththegenomicadjustedradiationdosegardmodel
AT osullivanbrian exploringbreastandprostatecancerrnaseqderivedradiosensitivitywiththegenomicadjustedradiationdosegardmodel
AT goldenaaron exploringbreastandprostatecancerrnaseqderivedradiosensitivitywiththegenomicadjustedradiationdosegardmodel